Jupiter Topco LLC Takes $883,000 Position in Omnicell, Inc. $OMCL

Jupiter Topco LLC bought a new position in Omnicell, Inc. (NASDAQ:OMCL) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 21,267 shares of the company’s stock, valued at approximately $883,000.

Several other large investors have also recently modified their holdings of the stock. Raymond James Financial Inc. bought a new stake in Omnicell in the second quarter worth $26,000. Versant Capital Management Inc increased its position in Omnicell by 38.7% during the second quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock valued at $44,000 after acquiring an additional 294 shares during the last quarter. Clearstead Advisors LLC increased its position in Omnicell by 12,180.0% during the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after acquiring an additional 1,218 shares during the last quarter. Kemnay Advisory Services Inc. purchased a new stake in shares of Omnicell in the fourth quarter valued at $58,000. Finally, Parkside Financial Bank & Trust raised its stake in shares of Omnicell by 1,708.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock valued at $61,000 after acquiring an additional 1,264 shares during the period. Institutional investors own 97.70% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Wells Fargo & Company dropped their price target on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Weiss Ratings upgraded Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 18th. Piper Sandler reaffirmed an “overweight” rating and set a $45.00 target price (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. Finally, Zacks Research downgraded Omnicell from a “hold” rating to a “strong sell” rating in a report on Friday, August 7th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Omnicell has a consensus rating of “Moderate Buy” and an average price target of $57.86.

Omnicell Trading Down 1.3%

NASDAQ OMCL opened at $34.37 on Friday. The stock has a market cap of $1.56 billion, a PE ratio of 40.92, a PEG ratio of 0.86 and a beta of 0.97. Omnicell, Inc. has a 12 month low of $29.06 and a 12 month high of $55.00. The company’s 50-day moving average price is $39.34 and its 200-day moving average price is $39.24. The company has a current ratio of 1.64, a quick ratio of 1.43 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47. The company had revenue of $312.21 million during the quarter, compared to analyst estimates of $310.21 million. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter last year, the business posted $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Equities research analysts forecast that Omnicell, Inc. will post 1.41 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.